News
Novo Nordisk Confidence in China Stays Strong Despite Drop in Weight-Loss Drug Sales, New CEO Says
China has massive unmet medical needs, Mike Doustdar, who took over as CEO of Novo Nordisk today, after previously leading its global operations, said at a second-quarter earnings conference call yesterday. The Bagsværd-based company will continue to strengthen its market position in the world's second-largest healthcare market, he added.
The pharmaceutical company's quarterly sales of its blockbuster Wegovy drug surged by two-thirds, despite many Americans ...
10hon MSN
Novo Nordisk ( NVO -4.02%) stock imitated the company's leading product on Wednesday by slimming down in price. The Danish pharmaceutical's shares lost nearly 4% of their value following its latest ...
Novo Nordisk CFO Karsten Munk Knudsen tells Yahoo Finance the company understands the pressure it is under to deliver better ...
Novo claims the defendants are steering patients toward compounded semaglutide that has not been approved by regulators; in ...
Novo Nordisk experiences heightened competition from copycat versions of its Wegovy obesity drug, affecting its market share, ...
Novo Nordisk A/S (NYSE:NVO) on Wednesday reported second-quarter 2025 sales of roughly $11.68 billion (76.86 billion Danish ...
The FDA says shortages of GLP-1s are over, but many patients are still getting what are essentially copied medications.
Stocktwits on MSN1d
Novo Nordisk Downgraded By UBS Over Uncertain Outlook For Wegovy, But Retail Prefers To Look At The Sunny SideNYSE-listed shares of Danish drugmaker Novo Nordisk (NVO) fell about 3% on Tuesday morning after brokerage UBS downgraded the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback